Compare · APGN vs NVO
APGN vs NVO
Side-by-side comparison of Apexigen Inc. (APGN) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APGN and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $195.34B.
- NVO has hit the wire 11 times in the past 4 weeks while APGN has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for APGN).
- Company
- Apexigen Inc.
- Novo Nordisk A/S
- Price
- $0.38+4.16%
- $44.29+5.43%
- Market cap
- -
- $195.34B
- 1M return
- -
- -2.57%
- 1Y return
- -
- -39.74%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 11
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest APGN
- SEC Form 15-12G filed by Apexigen Inc.
- SEC Form 4 filed by Zabrowksi Dan
- SEC Form 4: Wertheimer Samuel P returned 146,383 shares to the company, closing all direct ownership in the company
- SEC Form 4 filed by Smith Scott Andrew
- SEC Form 4: Ringold Gordon returned 10,000 shares to the company, closing all direct ownership in the company
- SEC Form 4 filed by Chhabra Meenu
- SEC Form 4 filed by Dupont Jakob
- SEC Form 4 filed by Cross Herb
- SEC Form 4: Wong Amy covered exercise/tax liability with 15,561 shares and returned 66,565 shares to the company, closing all direct ownership in the company
- SEC Form 4: Sarena Francis Willard covered exercise/tax liability with 31,123 shares and returned 124,296 shares to the company, closing all direct ownership in the company
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates